SCHEMBL1236262

SCHEMBL1236262

OCCCc1cccc(O)c1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IAPP P10997 4/20 0.53
ADAMTS4 O75173 1/20 0.46
ALDH1A1 P00352 1/20 0.46
EGFR P00533 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
LMNA P02545 1/20 0.46
FYN P06241 1/20 0.46
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
MMP8 P22894 1/20 0.46
CA6 P23280 1/20 0.46
CDK2 P24941 1/20 0.46
MMP12 P39900 1/20 0.46
RECQL P46063 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ADAMTS5 Q9UNA0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30810444 1.00 IAPP (0.53) IAPPADAMTS4ALDH1A1EGFRCA1
SCHEMBL9863155 0.92 IAPP (0.50) IAPP
SCHEMBL9863325 0.92 IAPP (0.50) IAPP
SCHEMBL10414030 0.89 IAPP (0.59) IAPPADAMTS4ALDH1A1EGFRCA1
SCHEMBL8894033 0.89 GABRA1 (0.48) IAPPALOX5PTGS2MPOSLC6A4
SCHEMBL1951548 0.86 IAPP (0.57) IAPPADAMTS4ALDH1A1EGFRCA1
SCHEMBL30046415 0.86 IAPP (0.57) IAPPADAMTS4ALDH1A1EGFRCA1
SCHEMBL9153692 0.82 ALOX5 (0.47) IAPPALOX5PTGS2
SCHEMBL169275 0.82 TAAR1 (0.58) CA2HSD17B10MPOSLC6A4HSPA5
SCHEMBL633288 0.81 TAAR1 (0.52) IAPPADAMTS4ALDH1A1EGFRCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103923072-A Substituted Indazole Derivatives Active As Kinase Inhibitors NERVIANO MEDICAL SCIENCES SRL 2014-07-16 CN disclosed
WO-2011022511-A2 METHODS OF REDUCING LIGNIN AND PRODUCTS THEREOF STRATEGIC ENZYME APPLICATIONS, INC. (US) 2011-02-24 WO disclosed
US-7777073-B2 Topical delivery system for antiaging and skin whitening agents BIODERM RESEARCH (US) 2010-08-17 US disclosed
US-20090074691-A1 Topical Delivery System for Antiaging and Skin Whitening Agents BIODERM RESEARCH (US) 2009-03-19 US disclosed
EP-0669331-B1 Benzodioxane derivatives, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 2000-10-11 EP disclosed
US-5500443-A SCHIZOPHRENIA ADIR ET COMPAGNIE (FR) 1996-03-19 US disclosed
EP-0669331-A1 Benzodioxane derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1995-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090074691-A1 Topical Delivery System for Antiaging and Skin Whitening Agents TYR, MMP17, MMP1 IAPP 2230/4885ADAMTS4 1319/4885ALDH1A1 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.